A novel precision medicine approach for obesity: a randomized, multi-center trial
Active Project Grant Awarded Last action
- Award ID
- R44DK138619
- Recipient
-
Phenomix Sciences LLC UEI DUKXPDE2HMU3
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,331,897
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date 88% complete
- Place of performance
- Chanhassen, MN 55317, USA
Award details come from USAspending.gov.
Description
- Abstract
- Obesity is a chronic, relapsing, and multifactorial DISEASE1, with a prevalence of 42%2. As with any obesity treatment, the weight loss response with anti-obesity medications (aoms) is highly variable. For example, semaglutide 2.4 MG, the most effective AOM leads to a mean total body weight loss (tbwl) of 15% in randomized clinical TRIALS3 and in real-world clinic cohort STUDIES4. However, only 50% of participants achieve >15% in one YEAR3, whereas 30% lose less than 10% tbwl. In the clinical practice, access to aoms can be limited by their high cost. Importantly, given the variable weight loss response to AOM, these may not be cost- effective, particularly in poor responders who will not only incur unnecessary high costs, but will also be exposed to possible side effects. Currently, besides identifying responders by trial-and-ERROR5, 6, little is known about the predictors of response to AOM, and the heterogeneous response to this type of intervention, remains an important challenge in clinical PRACTICE1, 7. There is a critical need to identify the predictors of response to AOM to develop individualized weight-loss strategies that enhance weight loss outcomes in people with OBESITY8. Our team focuses on understanding the heterogeneity of human obesity by identifying predictors of response to weight loss TREATMENTS9. Phenotyping of 880 adults has demonstrated that there are phenotypic traits that differentially respond to weight loss interventions. One of these phenotypic traits is abnormal postprandial SATIETY10 patients with abnormal postprandial satiety have increased postprandial hunger, which is associated with accelerated gastric EMPTYING11. To date, we have shown that lifestyle interventions, aoms, and endoscopic devices targeting this underlying phenotypic trait enhance weight loss outcomes in patients with OBESITY10, 12-20. Our data suggest that the phenotype-tailored approach could become a clinical approach for the treatment of obesity whereby individual patients are matched to treatments directed at the underlying phenotype. However, the current methods used to identify phenotypes are time-consuming, invasive, expensive, limited to a few academic centers, and not generally accessible for most patients. To address these limitations, an academic-industry partnership was established, and we have developed and validated a novel blood- and saliva-based biomarker test of appetite regulation in obesity that predicts the abnormal postprandial satiety phenotype. The current biomarker, named myphenome test, is ready for commercialization in a clia-cap accredited laboratory; and IT will be scalable and affordable to support healthcare providers to guide patients to tailored lifestyle interventions and aoms. Our aim is to study, in a multi- center, 12-month, prospective, randomized, double-blind, placebo-controlled trial, the efficacy of subcutaneous semaglutide 2.4 MG in patients with obesity with either a positive or a negative myphenome test for abnormal postprandial satiety. This step is essential in the final validation process of this novel biomarker prior to seeking third party reimbursement for its use to guide therapy for obesity.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $348,022 | |
| Amendment | $995,866 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $996,003 | |
| Amendment | $996,003 | |
| Original award | $996,003 |
Quick answers
Who received award R44DK138619?
R44DK138619 was awarded to Phenomix Sciences LLC by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on March 15, 2024.
How much is award R44DK138619 worth?
$4,331,897 has been obligated on R44DK138619.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award